Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives Consensus Rating of “Hold” from Brokerages

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have been given an average rating of “Hold” by the five brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $2.5833.

Several brokerages recently weighed in on VVOS. Ascendiant Capital Markets decreased their price objective on Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Monday, April 20th. Finally, HC Wainwright decreased their price objective on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a report on Friday, April 17th.

Insider Buying and Selling at Vivos Therapeutics

In related news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The shares were purchased at an average cost of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the transaction, the insider directly owned 1,353,625 shares in the company, valued at approximately $1,813,857.50. This represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 2.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vivos Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Acorn Wealth Advisors LLC bought a new stake in shares of Vivos Therapeutics during the fourth quarter valued at about $30,000. XTX Topco Ltd bought a new stake in shares of Vivos Therapeutics during the second quarter valued at about $65,000. Sequoia Financial Advisors LLC bought a new stake in shares of Vivos Therapeutics during the first quarter valued at about $28,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Vivos Therapeutics during the second quarter valued at about $220,000. Finally, DRW Securities LLC increased its position in shares of Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares during the period. 26.35% of the stock is currently owned by institutional investors.

Vivos Therapeutics Trading Down 7.1%

Shares of VVOS opened at $0.64 on Monday. The business has a 50-day moving average of $1.09 and a 200 day moving average of $1.69. Vivos Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $7.95. The firm has a market cap of $8.79 million, a P/E ratio of -0.31 and a beta of 6.25. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.24 and a current ratio of 0.24.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings data on Wednesday, April 15th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.08). Vivos Therapeutics had a negative return on equity of 849.22% and a negative net margin of 121.37%.The firm had revenue of $3.82 million during the quarter, compared to analysts’ expectations of $7.10 million. During the same period last year, the business posted ($2.22) EPS. As a group, research analysts forecast that Vivos Therapeutics will post -1.33 EPS for the current year.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.